Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells

被引:48
|
作者
He, Xiaocui [1 ,2 ]
Klaesener, Kathrin [1 ,2 ]
Iype, Joseena M. [1 ,3 ]
Becker, Martin [1 ,4 ]
Maity, Palash C. [1 ,3 ]
Cavallari, Marco [1 ]
Nielsen, Peter J. [2 ]
Yang, Jianying [1 ,2 ]
Reth, Michael [1 ,2 ]
机构
[1] Univ Freiburg, Biol 3, BIOSS Ctr Biol Signaling Studies, Fac Biol,Dept Mol Immunol, Freiburg, Germany
[2] Max Planck Inst Immunobiol & Epigenet, Freiburg, Germany
[3] Uni Hosp Ulm, Inst Immunol, Ulm, Germany
[4] Helmholtz Zentrum Munchen, Munich, Germany
来源
EMBO JOURNAL | 2018年 / 37卷 / 11期
基金
欧洲研究理事会;
关键词
B-cell antigen receptor; Burkitt lymphoma; Cas9; CRISPR; survival signal; tumor fitness; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN RECEPTOR; IG-ALPHA; IMMUNE-RESPONSE; BAFF-R; BETA; IMMUNOGLOBULIN; SURVIVAL; PROTEIN; MICE;
D O I
10.15252/embj.201797980
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Expression of the B-cell antigen receptor (BCR) is essential not only for the development but also for the maintenance of mature B cells. Similarly, many B-cell lymphomas, including Burkitt lymphoma (BL), require continuous BCR signaling for their tumor growth. This growth is driven by immunoreceptor tyrosine-based activation motif (ITAM) and PI3 kinase (PI3K) signaling. Here, we employ CRISPR/Cas9 to delete BCR and B-cell co-receptor genes in the human BL cell line Ramos. We find that Ramos B cells require the expression of the BCR signaling component Ig (CD79b), and the co-receptor CD19, for their fitness and competitive growth in culture. Furthermore, we show that in the absence of any other BCR component, Ig can be expressed on the B-cell surface, where it is found in close proximity to CD19 and signals in an ITAM-dependent manner. These data suggest that Ig and CD19 are part of an alternative B-cell signaling module that use continuous ITAM/PI3K signaling to promote the survival of B lymphoma and normal B cells.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
    Ormhoj, Maria
    Scarfo, Irene
    Cabral, Maria L.
    Bailey, Stefanie R.
    Lorrey, Selena J.
    Bouffard, Amanda A.
    Castano, Ana P.
    Larson, Rebecca C.
    Riley, Lauren S.
    Schmidts, Andrea
    Choi, Bryan D.
    Andersen, Rikke S.
    Cedile, Oriane
    Nyvold, Charlotte G.
    Christensen, Jacob H.
    Gjerstorff, Morten F.
    Ditzel, Henrik J.
    Weinstock, David M.
    Barington, Torben
    Frigault, Matthew J.
    Maus, Marcela V.
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7046 - 7057
  • [2] Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders
    Cabezudo, E
    Carrara, P
    Morilla, R
    Matutes, E
    HAEMATOLOGICA, 1999, 84 (05) : 413 - 418
  • [3] CD79B Mutation in Diffuse Large B-Cell Lymphoma
    Kim, Y.
    Ju, H.
    Kim, D-H
    Ko, Y-H
    LABORATORY INVESTIGATION, 2013, 93 : 336A - 336A
  • [4] CD79B Mutation in Diffuse Large B-Cell Lymphoma
    Kim, Y.
    Ju, H.
    Kim, D-H
    Ko, Y-H
    MODERN PATHOLOGY, 2013, 26 : 336A - 336A
  • [5] B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells
    Tkachenko, Anton
    Kupcova, Kristyna
    Havranek, Ondrej
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
  • [6] Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19 (vol 25, Pg 7046, 2019)
    Ormhoj, Maria
    Scarfo, Irene
    Cabral, Maria L.
    Bailey, Stefanie R.
    Lorrey, Selena J.
    Bouffard, Amanda A.
    Castano, Ana P.
    Larson, Rebecca C.
    Riley, Lauren S.
    Schmidts, Andrea
    Choi, Bryan D.
    Andersen, Rikke S.
    Cedile, Oriane
    Nyvold, Charlotte G.
    Christensen, Jacob H.
    Gjerstorff, Morten F.
    Ditzel, Henrik J.
    Weinstock, David M.
    Barington, Torben
    Frigault, Matthew J.
    Maus, Marcela V.
    CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2286 - 2286
  • [7] Mechanism of CD79A and CD79B Support for IgM plus B Cell Fitness through B Cell Receptor Surface Expression
    Huse, Kanutte
    Bai, Baoyan
    Hilden, Vera I.
    Bollum, Lise K.
    Vatsveen, Thea K.
    Munthe, Ludvig A.
    Smeland, Erlend B.
    Irish, Jonathan M.
    Walchli, Sebastien
    Myklebust, June H.
    JOURNAL OF IMMUNOLOGY, 2022, 209 (10): : 2042 - 2053
  • [8] Ongoing mutation of CD79b and CD79a genes in B-CLL.
    Yan, XJ
    McGuire, P
    Albesiano, E
    Petersen, D
    Damle, R
    Allen, SL
    Schulman, P
    Vinciguerra, V
    Rai, KR
    Ferrarini, M
    Chiorazzi, N
    BLOOD, 2000, 96 (11) : 836A - 836A
  • [9] CD79B limits response of diffuse large B cell lymphoma to ibrutinib
    Kim, Joo Hyun
    Kim, Won Seog
    Ryu, Kyungju
    Kim, Seok Jin
    Park, Chaehwa
    LEUKEMIA & LYMPHOMA, 2016, 57 (06) : 1413 - 1422
  • [10] POLYMORPHISMS IN CD79B GENE AND MS
    Mihalova, T.
    Woolmore, J. A.
    Stone, M.
    Eyre, S.
    Barton, A.
    Hoban, P.
    Worthington, J.
    Strange, R.
    Hawkins, C. P.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (01): : 124 - 124